NEWS & NOTICE

Newsroom

2020.07.13
[Press Relese] LSK Global PS Supports International Vaccine Institute (IVI) Clinical Trials of COVID-19 Vaccine in South Korea
Files : , press release_lsk global ps supports international vaccine institute (ivi) clinical trials of covid-19 vaccine in south korea_20200713.pdf

LSK Global PS Supports International Vaccine Institute (IVI) Clinical Trials of COVID-19 Vaccine in South Korea

-       Contracted by IVI as CRO to conduct phase 1/2 trial of INOVIO’s COVID-19 vaccine candidate (INO-4800)

-       Selected for its vast experience in vaccine clinical trials and expertise at the global and local levels

 

[July 13, 2020] LSK Global Pharma Services Co., Ltd. (LSK Global PS), a leading contract research organization (CRO) in Korea, announced that it has formed a partnership with the International Vaccine Institute (IVI) to support clinical trials for a COVID-19 vaccine on June 17, 2020.

 

The phase 1/2 clinical trial will involve INO-4800, a COVID-19 vaccine candidate currently being developed by INOVIO and the first vaccine that has been approved for clinical trials in Korea.

 

It is believed that a vaccine will provide a long-term solution to control the COVID-19 pandemic, and the call for a vaccine is growing amid the prolonged crisis which has continued for more than half a year.

 

While it usually takes about a decade for a vaccine to be successfully developed and distributed, many organizations have teamed up to accelerate development of a COVID-19 vaccine. The phase 1/2 clinical trial of INO-4800, funded by the Coalition for Epidemic Preparedness Innovations (CEPI) via INOVIO, will be led by IVI, Seoul National University Hospital and SNU Bundang Hospital and is supported by the Korea National Institute of Health for laboratory analysis.

 

IVI developed plans for clinical trials in Korea and quickly obtained approval from the Ministry of Food and Drug Safety and local Ethics Committees and has worked with SNU Hospital and SNU Bundang Hospital to begin the clinical trials as quickly as possible. As the CRO, LSK  Global PS will be responsible for general clinical operations of the trial, including project management, monitoring, data management and pharmacovigilance activities.

 

LSK Global PS was recognized for its rich experience in clinical trials of vaccines as well as its contributions as a leading CRO to the success of large-scale global clinical trials and its large, highly competent and well-trained workforce that is certified to conduct global clinical trials.


 

“We are pleased to begin this clinical trial following the selection of LSK Global PS and taking the next steps toward the development of a COVID-19 vaccine, which has been eagerly awaited by people across the world,” said Dr. Jerome H. Kim, Director General of IVI. “We believe that the clinical trial will be conducted quickly and accurately, bringing together top experts from  different fields.”

 

Young-Jack Lee, the president of LSK Global PS said, “We are honored to conduct the first approved clinical trial of a COVID-19 vaccine in Korea and play our role as a leading CRO in addressing the growing expectations for a COVID-19 vaccine,” adding, “We remain committed to successfully completing clinical trials with the extensive experience and capabilities we have built through more than 130 global clinical trials including various trials  of vaccines.”

 

 

                                                                                                    #  # #